Cocrystal Pharma, Inc. (COCP)
0.99
+0.04
(+4.21%)
USD |
NASDAQ |
Oct 26, 12:06
Cocrystal Pharma Enterprise Value : 12.20M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 12.20M |
| October 22, 2026 | 11.67M |
| October 21, 2026 | 12.11M |
| October 20, 2026 | 12.10M |
| October 19, 2026 | 12.15M |
| October 16, 2026 | 13.16M |
| October 15, 2026 | 13.30M |
| October 14, 2026 | 13.44M |
| October 13, 2026 | 13.99M |
| October 12, 2026 | 13.71M |
| October 09, 2026 | 13.85M |
| October 08, 2026 | 13.85M |
| October 07, 2026 | 13.71M |
| October 06, 2026 | 14.40M |
| October 05, 2026 | 14.40M |
| October 02, 2026 | 14.89M |
| October 01, 2026 | 14.82M |
| September 30, 2026 | 14.95M |
| September 29, 2026 | 14.54M |
| September 28, 2026 | 15.78M |
| September 25, 2026 | 15.23M |
| September 24, 2026 | 14.95M |
| September 23, 2026 | 15.51M |
| September 22, 2026 | 15.51M |
| September 21, 2026 | 15.51M |
| Date | Value |
|---|---|
| September 18, 2026 | 15.78M |
| September 17, 2026 | 14.82M |
| September 16, 2026 | 14.82M |
| September 15, 2026 | 14.82M |
| September 14, 2026 | 15.23M |
| September 11, 2026 | 16.20M |
| September 10, 2026 | 16.06M |
| September 09, 2026 | 16.20M |
| September 08, 2026 | 15.37M |
| September 04, 2026 | 14.68M |
| September 03, 2026 | 14.68M |
| September 02, 2026 | 15.09M |
| September 01, 2026 | 14.54M |
| August 31, 2026 | 15.09M |
| August 28, 2026 | 14.26M |
| August 27, 2026 | 14.82M |
| August 26, 2026 | 14.54M |
| August 25, 2026 | 14.68M |
| August 24, 2026 | 14.40M |
| August 21, 2026 | 14.95M |
| August 20, 2026 | 15.23M |
| August 19, 2026 | 14.89M |
| August 18, 2026 | 13.99M |
| August 17, 2026 | 14.13M |
| August 14, 2026 | 14.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| CNBX Pharmaceuticals, Inc. | 1.305M |
| Arvinas, Inc. | -83.01M |
| Fulcrum Therapeutics, Inc. | -32.83M |
| Definium Therapeutics, Inc. | 3.745B |
| LeonaBio, Inc. | -4.889M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.164M |
| Revenue (Quarterly) | 0.105M |
| Total Expenses (Quarterly) | 3.269M |
| EPS Diluted (Quarterly) | -0.2295 |
| Gross Profit Margin (Quarterly) | 88.57% |
| Profit Margin (Quarterly) | -3.01K% |
| Earnings Yield | -76.64% |
| Normalized Earnings Yield | -76.64 |